Alexion Pharmaceuticals Inc. (ALXN) Falls 3.32% for January 28

Equities Staff  |

One of the S&P 500’s big losers for Thursday January 28 was Alexion Pharmaceuticals Inc. (ALXN). The company’s stock fell 3.32% to $146.11 on volume of 2.21 million shares.

The stock opened the day at 151.96 and traded between a low of $143.03 and a high of $155.00. The stock finished the day down $5.01 per share. Alexion Pharmaceuticals Inc. has an average daily volume of 1.62 million and a total float of 225.32 million shares. The 50-day SMA for Alexion Pharmaceuticals Inc. is $175.93 and its 200-day SMA is $175.58. The high for the stock over the last 52 weeks is $208.88 and the low is $142.02.

Alexion Pharmaceuticals Inc is a biopharmaceutical company engaged in serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.

Alexion Pharmaceuticals Inc. is centered in Cheshire, CT, and has 2,273 employees. Today’s trading day leaves the company with a market cap of $32.92 billion. The company has a P/S ratio of n/a, P/B ratio of 3.99, and a -9.4.

For a complete fundamental analysis analysis of Alexion Pharmaceuticals Inc., check out’s Stock Valuation Analysis report for ALXN. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.

While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:



Symbol Last Price Change % Change










World Economic Forum at Davos 2019 - Dominic Briggs General Partner Blockwall Management

Matt Bird sits down with Dominic Briggs, General Partner Blockwall Management at the World Economic Forum at Davos 2019

Emerging Growth

IMV Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.